Shares of Immuron Limited (NASDAQ:IMRN) are surging Friday morning following news that the Australian biopharmaceutical company signed an exclusive agreement to launch PROIBS gut health product in the United States. Here’s what investors need to know.
- Immuron stock is surging to new heights today. What’s driving IMRN stock higher?
Exclusive Partnership Targets $4.16 Billion U.S. Gut Health Market
According to a Friday announcement, Immuron executed an exclusive distribution agreement with Sweden-based Calmino group AB. The deal expands on Immuron’s initial launch of PROIBS in Australia during fiscal year 2026, targeting a high-demand segment of the $4.16 billion U.S. digestive health supplement market.
PROIBS is a European-certified medical device designed for abdominal pain, bloating and unsettled bowel movements. Its active ingredient, AVH200, is derived from Aloe barbadensis Mill. and features gel-forming components that support the intestinal mucosal barrier.
Per the company, in a usability study of 1,003 participants conducted by Calmino, 94% of users reported that PROIBS was helpful, with 91% experiencing improvements in daily life and 98% stating they would recommend the product.
Management Commentary Points to Expanding U.S. Commercial Footprint
Flavio Palumbo, Chief Commercial Officer of Immuron, highlighted the expansion: “Following the rapid growth of Travelan sales in the US, we have developed a commercial growth strategy to bring a portfolio of innovative digestive health products to market. PROIBS is a great opportunity to further expand our digestive health portfolio by providing our customers with a proven premium product that delivers improvement in daily life.”
Tobias Kisker, CEO and founder of Calmino group AB, added: “We are immensely proud to further expand our collaboration with Immuron. What started with PROIBS in Australia is now developing into a partnership across two continents, with the United States becoming our next important market together.”
IMRN Stock Skyrockets Friday Morning
IMRN Price Action: Immuron shares were up 57.66% at $1.75 during premarket trading on Friday, according to Benzinga Pro data.
Image: Shutterstock
